Oxford Immunotec Global PLC (NASDAQ:OXFD)’s share price gapped up prior to trading on Monday . The stock had previously closed at $8.74, but opened at $8.82. Oxford Immunotec Global PLC shares last traded at $8.97, with a volume of 18,090 shares trading hands.

OXFD has been the topic of several recent analyst reports. Zacks Investment Research raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Wednesday, May 4th. BTIG Research reaffirmed a “buy” rating and set a $17.00 price objective on shares of Oxford Immunotec Global PLC in a report on Monday, June 27th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th.

The stock’s market cap is $202.42 million. The stock has a 50-day moving average of $8.95 and a 200 day moving average of $9.93.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.32) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.32). The company earned $17.10 million during the quarter, compared to analyst estimates of $16.96 million. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.31) EPS. On average, equities research analysts forecast that Oxford Immunotec Global PLC will post ($1.28) EPS for the current year.

A hedge fund recently raised its stake in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. raised its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned about 4.74% of Oxford Immunotec Global PLC worth $12,293,000 as of its most recent filing with the SEC.

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.